CA
NZ
UK
AU
IND
US
Galera Therapeutics, Inc. raised roughly $350 million by selling Series C non‑voting convertible preferred stock in a private placement, expanding its cash reserves just days before the scheduled merger. The infusion arrives at a critical juncture, providing the liquidity needed to close the transaction …
Investors gain a refreshedLeadershipteam and a tighter share structure that could enhance liquidity and appeal amid the stock’s strong rally.
Inmune Bio, Inc. has received a $4.2 million research and development cash rebate from the Australian government, substantially improving its liquidity for future initiatives. The positive financial impact aids Inmune Bio's operationalCash Flow, allowing for continuedInvestmentin advancing its pipeline without resorting toEquity Financing. As …
Bristol Myers Squibb reported second-quarter revenues of $13.0 billion, marking a 6% increase over the previous year. This growth has been significantly bolstered by a 15% rise in earnings from its Growth Portfolio, which totaled $7.6 billion. The impressive figures are indicative of the …
The cyclospora outbreak has reached unprecedented levels, marking the largest outbreak on record. With questions emerging about the outbreak's potential to last longer than previous instances, which typically resolved by August, stakeholders in food supply and safety are on high alert. This situation poses …
Daiichi Sankyo Company, Limited recently conducted its earnings call for the first quarter of fiscal year 2026. Management detailed the company’s strategic focus on enhancing its presence in various therapeutic areas, particularly oncology. This focus is poised to improve its market position amid competitive …
Q2 Results Indicate Strong Performance
Anteris Technologies Global Corp. (NASDAQ: AVR) is facing scrutiny following the issuance of 44,068 CHESS Depositary Interests (CDIs) on July 10, 2026, which occurred amid an administrative oversight regarding a required cleansing notice. This incident has drawn attention as it raises compliance questions, although …
The news sparked investor concerns about the potential impact of the deal on AstraZeneca's future. This earnings beat may be overshadowed by the merger talks, as investors weigh the potential benefits and risks of the deal, which could lead to increasedVolatilityin the company's shares.
Beyond Air, Inc. (NASDAQ: XAIR) has successfully secured approximately $10.2 million through a private placement of stock and warrants. The deal is set to close on July 31, 2026, providing essential capital for ongoing operations and development initiatives.
Please wait processing your request...